Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy.
Multiple changes in the coagulation system occur during pregnancy and account for the hypercoagulable state of pregnancy. Consequently, pregnant women are five times more likely to experience venous thromboembolism than non-pregnant women. Although the estimated rates of such events are low, venous thromboembolic disease is a leading cause of maternal death. The administration of intravenous or subcutaneous unfractionated heparin is the treatment and prophylaxis of choice. Warfarin is safe and efficacious following delivery, but should be avoided during pregnancy. LMWH is a promising alternative for treatment and prophylaxis, but further clinical experience is required.
Burns
M M
MM
UMASS Memorial Health Care Division of Cardiology, Worcester, MA, USA.
D000925:Anticoagulants / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis* / Q000628:therapy*; D013923:Thromboembolism / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D019851:Thrombophilia / Q000188:drug therapy; D020246:Venous Thrombosis / Q000175:diagnosis / Q000628:therapy
D000925:Anticoagulants; D005343:Fibrinolytic Agents